Skip to content

Clinical Study of Good Monk H50+ and H50+2.0 on healthy human participants of age group of 50-70 yrs.

A Randomized, Double Blind, Placebo Controlled Parallel Clinical Trial to evaluate the Safety and Efficacy of Good Monk Healthy 50+ and Good Monk Healthy 50+2.0 Premixes in Aged (50-70 yr) Healthy Population.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104349
Enrollment
150
Registered
2026-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Good Monk Healthy H50+: 2.3g of proprietary premix formulation of micronutrients, probiotics, essential amino acids and herbs to be consumed orally twice daily with food for 120 days. I

Sponsors

Superfoods Valley Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy male or female subjects in the age group of 50-70 yrs. with a Body Mass Index (BMI) between 18 to 29.9 kg/m2. 2. Subjects who meet at least any of the two important micronutrient deficiency (Vit.B12, Vit.D, Iron) and/or a gut related dysfunction or the combination of both. 3. Subjects, who are in good health conditions at the time of enrolment into the study as determined from medical history, physical examination and clinical judgment of the investigator. 4. Diabetic and Hypertensive subjects who are stable with the normal diet and regular concomitant medication and considered otherwise healthy by the treating Investigator.

Exclusion criteria

Exclusion criteria: 1. Subjects with the current habit or history of cigarette smoking and alcohol consumption. 2. Subjects with any known significant systemic disease/ disorder, i.e. hepatic, renal, oesophageal, gastrointestinal, cardiovascular, psychological, neurological etc. other than diabetes and hypertension. 3. Subjects on any seizure medication. 4. Subjects with a known history of any malignant disease. 5. Subjects with known history of autoimmune disease and other systemic diseases related to immune system or on any medication known to reduce immunoglobulin levels or with known chronic immune diseases like HIV, HBsAg, HCV, etc. 6. Subjects treated with the following medications: a) Antibiotics less than one week before the study b) Any vaccination less than 4 weeks before the study c) Concomitant immunosuppressive or immune-stimulating therapy 3 months before the study start. d) Concomitant medication/ therapy for gut related disorder/s. e) Concomitant medication/ therapy for micronutrient supplementation. 7. Subjects who participated in another clinical trial less than 3 months prior to this study. 8. Subjects with the history of consumption of any recreational drugs (such as cocaine, methamphetamine, marijuana, etc). 9. Subjects who are scheduled for any surgery within 3 months period of completing the study. 10. Subjects with inability or unwillingness to abide by the requirements of the protocol. 11. Subjects who are incompetent to sign an Informed Consent Form. 12. Any criteria, which in the opinion of the Investigator, suggests that the subject would not be compliant with the study protocol.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects showing improvement at the end of the study compared to the baseline through energy & mobility tests, gut health parameters, immunity and inflammatory biomarkers.Timepoint: 0 Day, 30 Day, 60 day, 90 Day and 120 Day

Secondary

MeasureTime frame
Proportion of subjects showing improvement at the end of the study compared to the baseline by assessing through micronutrient levels, mental & stress assessment tests and safety laboratory testsTimepoint: 0 Day, 30 Day, 60 day, 90 Day and 120 Day

Countries

India

Contacts

Public ContactDr Shovan Ganguli

Superfoods Valley Private Limited

shovan.ganguli@gmail.com9611533150

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026